Acitretin

證據等級: L5

預測適應症: 10 個

Acitretin: From Psoriasis to Acne

One-Sentence Summary

Acitretin is a second-generation oral retinoid (synthetic vitamin A derivative) used internationally as a primary treatment for severe, recalcitrant psoriasis and disorders of keratinisation. The TxGNN model predicts it may have efficacy for acne (disease) — encompassing both acne vulgaris and acne inversa (hidradenitis suppurativa) — with 1 registered clinical trial and 18 publications identified in support; however, the clinical trial is not directly relevant to acitretin, and the bulk of literature addresses acne inversa rather than acne vulgaris. This distinction is clinically significant and requires careful consideration before any repurposing decision.

Quick Overview

Item	Content
Original Indication	Psoriasis and disorders of keratinisation (based on known pharmacology; not extractable from ARTG — no current entries found)
Predicted New Indication	Acne (disease)
TxGNN Prediction Score	99.94%
Evidence Level	L3
Australia Market Status	Not registered (0 ARTG entries found — verify against live ARTG)
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Acitretin is a retinoic acid receptor (RAR) agonist — the active metabolite of etretinate — that binds nuclear RAR-α, RAR-β, and RAR-γ receptors. Through this mechanism, it normalises keratinocyte differentiation and proliferation, suppresses sebaceous gland activity, and exerts anti-inflammatory effects, including inhibition of eosinophil leukotriene C4 (LTC4) production. These actions target core pathological processes in acne: excess sebum production, abnormal follicular keratinisation, and follicular inflammation. In this respect, acitretin’s mechanism of action overlaps substantially with isotretinoin, the retinoid most commonly associated with acne vulgaris treatment.

The prediction is better supported for acne inversa (hidradenitis suppurativa/HS) than for acne vulgaris. HS is a chronic, debilitating inflammatory disease of the hair follicle in apocrine gland-bearing skin (axillae, groin, perianal region) and is sometimes classified as a severe variant of acne-related pathology. Acitretin’s dual activity — suppressing follicular keratinisation and modulating the inflammatory microenvironment — provides a rational mechanistic basis for its use in HS. Long-term case series spanning 25 years (Boer & Nazary, 2011) and inclusion in European S1 clinical guidelines support this indication.

For acne vulgaris specifically, the evidence is more limited. Isotretinoin remains the retinoid of choice due to its superior sebosuppressive potency and extensive clinical trial data. Acitretin’s primary dermatological role has historically been psoriasis and keratinisation disorders, and the literature does not strongly support it as a standalone treatment for common acne vulgaris. Clinicians reviewing this report should therefore treat the acne (disease) prediction as most applicable to the acne inversa subtype.

Clinical Trial Evidence

⚠️ Data Quality Alert: The only clinical trial returned by the search (NCT04663906) investigates oral isotretinoin (not acitretin) and its association with COVID-19 infection risk — it has no relevance to acitretin’s use in acne. Its trial status is UNKNOWN and it should not be counted as supporting evidence.

Currently no directly relevant clinical trials investigating acitretin for acne (vulgaris or inversa) are registered on ClinicalTrials.gov or ANZCTR.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
20874789	2011	Case Series / Retrospective	British Journal of Dermatology	Long-term results of acitretin for hidradenitis suppurativa (acne inversa) over 25 years — demonstrates sustained clinical benefit, contrasts with limited effectiveness of isotretinoin in HS
12080949	2002	Case Report	Cutis	Acitretin used for combined nodulocystic facial acne and HS after two failed isotretinoin courses — partial improvement of both conditions reported
25640693	2015	Clinical Guideline (S1)	J Eur Acad Dermatol Venereol	European S1 guideline for hidradenitis suppurativa/acne inversa — establishes retinoids (including acitretin) within the treatment algorithm
29234829	2018	Review	Der Hautarzt	Drug therapy review for acne inversa; acitretin discussed alongside antibiotics (clindamycin/rifampicin) and adalimumab as therapeutic options
26617362	2016	Review	Dermatologic Clinics	Medical treatments of HS reviewed — highlights the low evidence level across therapies including retinoids and advocates for validation via RCTs
8573927	1995	Mechanistic Review	Dermatology	Reviews retinoid inhibition of sebaceous gland activity — examines whether the anti-acne effect of newer retinoids (including acitretin) can be predicted from experimental models
9074840	1997	Review	Drugs	Comprehensive review of retinoid use in dermatology covering psoriasis, severe acne, and keratotic disorders — acitretin positioned as the second-generation systemic retinoid
41692081	2026	Review	Clinics in Dermatology	Up-to-date review of vitamin A and retinoids in dermatology — covers acitretin alongside isotretinoin, alitretinoin, and bexarotene with current therapeutic context
1617858	1992	Pharmacokinetic Study	Clinical Pharmacokinetics	Pharmacokinetic profiles of acitretin and etretinate — confirms isotretinoin preferred for severe recalcitrant acne; acitretin’s major application is psoriasis
2112772	1990	Mechanistic Study	Prostaglandins	Acitretin inhibits eosinophil LTC4 production — provides biochemical evidence for the anti-inflammatory mechanism underpinning retinoid efficacy in acne and psoriasis

Australia Market Information

Acitretin was not found on the Australian Register of Therapeutic Goods (ARTG) in this dataset (0 entries, market status: not registered).

⚠️ Important — Verify Current ARTG Status: This data should be confirmed against the live TGA ARTG database at https://www.tga.gov.au/resources/artg, as acitretin (brand name Neotigason) has historically been marketed in Australia. If the drug is registered, TGA-approved Product Information and current approved indications will be available through the ARTG public summary. If it is genuinely not registered, access for individual patients may be possible via the TGA Special Access Scheme (SAS Category B or C) or through an Authorised Prescriber arrangement.

Safety Considerations

Detailed safety data (TGA-approved warnings, contraindications, and drug interactions) were not available in this Evidence Pack.

Please refer to the TGA-approved Product Information (PI) for comprehensive safety information. Based on the well-established pharmacology of acitretin as a systemic retinoid, Australian prescribers should be aware of the following key issues:

Teratogenicity (Critical): Acitretin is an absolute contraindication in pregnancy and in women of childbearing potential who are not using highly effective contraception. Unlike isotretinoin, a unique risk with acitretin is its potential trans-esterification to etretinate (a long-acting teratogen) — particularly when combined with alcohol — which can extend the teratogenicity risk period to years after cessation.
Alcohol interaction: Concurrent alcohol consumption dramatically extends the teratogenicity risk window by enabling conversion to etretinate.
Hepatotoxicity: Baseline and periodic liver function monitoring is required.
Dyslipidaemia: Triglycerides and total cholesterol should be monitored during treatment.
Mucocutaneous dryness: Cheilitis, xerosis, and ocular dryness are common and expected class effects.

These safety notes reflect established retinoid pharmacology and do not substitute for the TGA-approved PI or clinical judgement.

Conclusion and Next Steps

Decision: Hold

Rationale: While acitretin has genuine mechanistic plausibility for acne (through RAR-mediated sebosuppression and anti-inflammatory activity), the current evidence base is limited to case series, case reports, and expert guidelines — primarily for acne inversa (hidradenitis suppurativa), not acne vulgaris. No randomised controlled trials for acitretin in any acne indication have been identified, and its ARTG registration status in Australia requires urgent verification before any clinical pathway can be established.

To proceed, the following is needed:

Verify ARTG registration: Confirm current TGA ARTG status for acitretin (Neotigason) and retrieve the TGA-approved PI with the full Australian indication list, warnings, and contraindications
Clarify target indication: Determine whether the repurposing question is for acne vulgaris or acne inversa (HS) — these have substantially different evidence profiles, existing treatment guidelines, and clinical urgency; the strongest case exists for acne inversa
Retrieve MOA data: Obtain complete mechanistic data from DrugBank (currently a data gap) to strengthen the mechanistic rationale section
Conduct a targeted literature review: Specifically search for acitretin (not isotretinoin or retinoids broadly) in acne vulgaris to determine whether any direct comparative or interventional evidence exists
Access pathway assessment: If clinical use is being considered, identify whether SAS or Authorised Prescriber status would be required given the absence of an ARTG-registered acne indication
Specialist review: Engage Australian dermatology specialists with experience in HS management to assess the clinical utility of acitretin relative to currently available agents (adalimumab, antibiotics)

⚠️ Disclaimer: This report is for research and evaluation purposes only and does not constitute medical advice. Drug repurposing candidates require formal clinical validation before therapeutic application. All prescribing decisions should be made in accordance with TGA-approved Product Information and current clinical guidelines.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.